On Jul. 8, 2022, Pfizer and BioNTech announced that the companies had submitted a variation to the European…
On Jul. 7, 2022, Novavax announced that the European Commission had approved a variation to allow SK bioscience…
On Jul. 5, 2022, Novavax announced announced that the European Commission had approved the expanded conditional marketing authorization…
On Jul. 5, 2022, the National Institutes of Health and National Cancer Institute announced COVID-19 was the third…
On Jul. 5, 2022, the National Institutes of Health released a study that described the immune response triggered…
On Jun. 30 2022, Pfizer announced the submission of a New Drug Application (NDA) to the U.S. Food…
On Jun. 30, 2022, Pfizer and BioNTech announced a vaccine supply agreement with the U.S. government to support…
On Jun. 30, 2022, BD (Becton, Dickinson) announced that the BD MAX Respiratory Viral Panel (RVP), a new…
Play the COVID-19 Wheel of Fortune and see how lucky you are! You have two wheels to choose…
On Jun. 24 2022, Pfizer and BioNTech announced positive data evaluating the safety, tolerability, and immunogenicity of two…
On Jun. 23 2022, Novavax announced the filing of a Supplement to a New Drug Submission with Health…
On Jun. 23 2022, Novavax announced that the Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had been recommended for expanded conditional…
On Jun. 23 2022, Novavax announced that the Taiwan Food and Drug Administration had granted emergency use authorization…
On Jun. 23, 2022, Innovation Pharmaceuticals reported that Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity,…
On Jun. 17, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…
On Jun. 17, 2022, Pfizer and BioNTech announced the U.S. Food and Drug Administration had granted emergency use…
On Jun. 15, 2022, Pfizer and BioNTech announced the European Medicines Agency (EMA) had initiated a rolling review…
On Jun. 15, 2022, Roche announced that the US Food and Drug Administration had issued Emergency Use Authorization…
On Jun. 14 2022, Pfizer reported data from the Phase 2/3 EPIC-SR (Evaluation of Protease Inhibition for COVID-19…
On Jun. 13 2022, Novavax announced that the Australian Therapeutic Goods Administration (TGA) has granted provisional registration of…
On Jun. 8, 2022, Moderna announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing…
On Jun. 7, 2022, Merck and Ridgeback Biotherapeutics announced the Annals of Internal Medicine had published additional data…
On Jun. 7, 2022, Veru announced that is had submitted an emergency use authorization (EUA) application to the…
On Jun. 6, 2022, Pfizer further strengthened its commitment to United States manufacturing with a $120 million investment…
On Jun. 4, 2022, researchers reported that in areas with large cattle populations and a high prevalence of…
On Jun. 2, 2022, Moderna announced an agreement with the European Commission (EC) to amend their originally agreed…
On Jun. 2, 2022, Novavax announced the submission of a request to the Medicines and Healthcare products Regulatory…
On Jun. 2, 2022, the U.S. National Institutes of Health announced that a large randomized, placebo-controlled clinical trial…
On Jun. 1, 2022, the U.S. National Institutes of Health announced that an NIH funded study had found…
On May 31, 2022, Moderna and Takeda announced the transfer of the marketing authorization for Moderna’s COVID-19 vaccine…